Experience of effective correction of the main manifestations of postcovid syndrome

Introduction. Postcovid syndrome is an urgent problem, due to its high frequency regardless of the severity of the infection and the age of the patient.

Aim. To evaluate the efficacy and safety of the use of a dietary supplement Metabovit^® Healthy Sleep with Glycine and Zinc in patients with postcovid syndrome.

Materials and methods. 50 patients with postcovid syndrome were included in the study, after randomization, Metabovit^® Healthy Sleep was added to therapy in group 1 (2 tablets 3 times a day), in group 2 patients received basic therapy for chronic diseases. The duration of observation was 21 days. Before and after the end of the study all patients underwent clinical and neuropsychological examination, which included: complaint analysis, the “Schulte tables” test, a verbal association test, a Trail Making Test, an MFI-20 self-questionnaire, a Reader test, a questionnaire on the level of life exhaustion, a hospital scale of anxiety and depression (HADS).

Results. In the group of patients receiving Metabovit^® Healthy Sleep 2 tablets 3 times a day, in comparison with the control group, the overall MFI-20 self-questionnaire score sugnificantly (p < 0.001) decreased by 16 [-19, -8] to 59 [52; 63] points performance time of "Schulte tables" test decreased by more than 13 seconds; performance time of the Trail Making Test was 26 seconds faster in part A and 40 seconds faster in part B, in the verbal association test, the results reached normative values for most participants; stress levels decreased by almost 25% in men and 11% in women; the indicator of life exhaustion decreased by 22%; the level of anxiety (HADS score) decreased by 5 [-7; -3] points which led to the normalization of this indicator in almost all participants of the group. By the end of the study, no significant changes in the studied parameters were detected in patients of the control group.

Conclusion. In the group of patients who received the Metabovit^® Healthy Sleep dietary supplement, there was a significant positive dynamics and regression of most of the symptoms of postcovid syndrome, in comparison with the control group.

1. Sudre C.H., Murray B., Varsavsky T., Graham M.S., Penfold R.S., Bowyer R.C. et al. Attributes and predictors of Long- COVID. Nat Med. 2021;27(4):626–631. https://doi.org/10.1038/s41591-021-01292-y.

2. Huang C., Huang L., Wang Y., Li X., Ren L., Gu X. et al. 6-month consequences of COVID- 19 in patients discharged from hospital: a cohort study. Lancet. 2021;397(10270):220–232. https://doi.org/10.1016/S0140-6736(20)32656-8.

3. Shishkova V.N., Dranitsina B.G. Postcovid cognitive impairment. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2022;(12):45–49. (In Russ.) https://doi.org/10.17116/jnevro202212212145.

4. Davis H.E., Assaf G.S., Mccorkell L., Wei H., Low R.J., Re’em Y. et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021;38:101019. https://doi.org/10.1016/j.eclinm.2021.101019.

5. Simani L., Ramezani M., Alavi I., Sagharichi V., Aalipour V.F., Ghorbani F., Pakdaman H. Prevalence and correlates of chronic fatigue syndrome and posttraumatic stress disorder after the outbreak of the COVID-1 9. J Neurovirol. 2021;27(1):154–159. https://doi.org/10.1007/s13365-021-00949-1.

6. Nakamura Z.M., Nash R.P., Laughon S.L., Rosenstein D.L. Neuropsychiatric complications of COVID- 19. Curr Psychiatry Rep. 2021;23(5):25. https://doi.org/10.1007/s11920-021-01237-9.

7. Fernandez-de-las- Peñas C., Palacios-Ceña D., Gomez-M ayordomo V., Rodríuez- Jiménez J., Palacios- Ceña M., Velasco- Arribas M. et al. Long-term post- COVID symptoms and associated risk factors in previously hospitalized patients: A multicenter study. J Infect. 2021;83(2):237–279. https://doi.org/10.1016/j.jinf.2021.04.036.

8. Halpin S.J., Mcivor C., Whyatt G., Adams A., Harvey O., McLean L. et al. Postdischarge symptoms and rehabilitation needs in survivors of COVID- 19 infection: A cross- sectional evaluation. J Med Virol. 2021;93(2):1013–1022. https://doi.org/10.1002/jmv.26368.

9. Humphreys H., Kilby L., Kudiersky N., Copeland R. Long COVID and the role of physical activity: a qualitative study. BMJ Open. 2021;11(3):e047632. https://doi.org/10.1136/bmjopen-2020-047632.

10. Shishkova V.N., Imamgayazova K.E., Kapustina L.A. Correction of psychoemotional disorders and short-term prognosis in patients with COVID- 19. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2022;122(5):63–68. (In Russ.) https://doi.org/10.17116/jnevro202212205163.

11. Shishkova V.N. Aspects of post- COVID asthenia symptoms correction. Therapy. 2022;(5):151–156. (In Russ.) https://doi.org/10.18565/therapy.2022.5.151-156.

12. Vertkin A.L., Shishkova V.N., Sycheva A.S., Kebina A.L., Nosova A.V., Uryanskaya K.A. et al. Options of metabolic support in case of coronaviral infection. Therapy. 2020;(7):154–163. (In Russ.) https://doi.org/10.18565/therapy.2020.7.146-155.

13. Geldysh T.G., Slozhenkina M.I., Spesivtseva E.V., Krinitskaya N.V. The use of glycine as a food additive in foods for schoolchildren and adolescents. Izvestia Vuzov. Food Technology. 2006;(4):67–70. (In Russ.) Available at: https://cyberleninka.ru/article/n/ispolzovanie-glitsina-v-kachestve-pischevoy-dobavki-v-produktah-dlya-pitaniya-shkolnikov-i-podrostkov?ysclid=ljbqg0n9dq806773954.

14. Lysikov Yu.A. Amino acids in human nutrition. Experimental and Clinical Gastroenterology. 2012;(2):88–105. (In Russ.) Available at: https://cyberleninka.ru/article/n/aminokisloty-v-pitanii-cheloveka?ysclid=ljbqnk0n16857877554.

15. Grigorova O.V., Romasenko L.V., Fayzulloev A.Z., Vazagaeva T.I., Maksimova L.N., Narcissov Ya.R. The use of Glycine in the treatment of patients suffering from adaptation disorder. Practical medicine. 2012;(2):178–182. (In Russ.) Available at: https://cyberleninka.ru/article/n/primenenie-glitsina-vlechenii-patsientov-stradayuschih-rasstroystvom-adaptatsii?ysclid=ljbqt3o1yz749309271.

16. Bannai M., Kawai N. New therapeutic strategy for amino acid medicine: glycine improves the quality of sleep. J Pharmacol Sci. 2012;118(2):145–148. https://doi.org/10.1254/jphs.11r04fm.

17. Razak M.A., Begum P.S., Viswanath B., Rajagopal S. Multifarious Beneficial Effect of Nonessential Amino Acid, Glycine: A Review. Oxid Med Cell Longev. 2017;2017:1716701. https://doi.org/10.1155/2017/1716701.

18. Pérez- Torres I., Zuniga-M unoz A.M., Guarner- Lans V. Beneficial Effects of the Amino Acid Glycine. Mini Rev Med. Chem. 2017;17(1):15–32. https://doi.org/10.2174/1389557516666160609081602.

19. Grigorova O.V., Romasenko L.V., Vazagaeva T.I., Maksimova L.N., Narcissov Ya.R. Effectiveness of anxiety therapy in patients suffering from adaptation disorder on a glycine therapy model taking into account placebo-r eactivity. Russian Journal of Psychiatry. 2012;(4):45–52. (In Russ.) Available at: https://cyberleninka.ru/article/n/effektivnost-terapii-trevogi-u-patsientov-stradayuschih-rasstroystvom-adaptatsii-na-modeli-terapii-glitsinom-suchetom-platsebo?ysclid=ljbrhac6bj548941965.

20. Prasad A. Discovery of Human Zinc Deficiency: Its Impact on Human Health and Disease. Adv Nutr. 2013;4(2):176–190. https://doi.org/10.3945/an.112.003210.

21. Hara T., Takeda T., Takagishi T., Fukue K., Kambe T., Fukada T. Physiological roles of zinc transporters: molecular and genetic importance in zinc homeostasis. J Physiol Sci. 2017;67(2):283–301. https://doi.org/10.1007/s12576-017-0521-4.

22. Pfaender S., Sauer A.K., Hagmeyer S., Mangus K., Linta L., Liebau S. et al. Zinc deficiency and low enterocyte zinc transporter expression in human patients with autism related mutations in SHANK3. Sci Rep. 2017;7:45190. https://doi.org/10.1038/srep45190.

23. Asl S.H., Nikfarjam S., Majidi Zolbanin N., Nassir R., Jafari R. Immunopharmacological perspective on zinc in SARS-CoV-2 infection. Int Immunopharmacol. 2021;96:107630. https://doi.org/10.1016/j.intimp.2021.107630.

24. Fathi M., Alavinejad P., Haidari Z., Amani R. The effects of zinc supplementation on metabolic profile and oxidative stress in overweight/obese patients with non-alcoholic fatty liver disease: A randomized, double- blind, placebo- controlled trial. J Trace Elem Med Biol. 2020;62:126635. https://doi.org/10.1016/j.jtemb.2020.126635.

25. Barbara M., Mindikoglu A.L. The role of zinc in the prevention and treatment of nonalcoholic fatty liver disease. Metabol Open. 2021;11:100105. https://doi.org/10.1016/j.metop.2021.100105.

26. Osuna- Padilla I.A., Briceño O., Aguilar- Vargas A., Rodríguez- Moguel N.C., Villazon- De la Rosa A., Pinto-C ardoso S. et al. Zinc and selenium indicators and their relation to immunologic and metabolic parameters in male patients with human immunodeficiency virus. Nutrition. 2020;70:110585. https://doi.org/10.1016/j.nut.2019.110585.

27. Pang W., Leng X., Lu H., Yang H., Song N., Tan L. et al. Depletion of intracellular zinc induces apoptosis of cultured hippocampal neurons through suppression of ERK signaling pathway and activation of caspase-3. Neurosci Lett. 2013;552:140–145. https://doi.org/10.1016/j.neulet.2013.07.057.

28. Faber S., Zinn G.M., Kern J.C., Skip Kingston H.M. The plasma zinc/serum copper ratio as a biomarker in children with autism spectrum disorders. Biomarkers. 2009;14(3):171–180. https://doi.org/10.1080/13547500902783747.

29. Faghfouri A.H., Zarezadeh M., Aghapour B., Izadi A., Rostamkhani H., Majnouni A. et al. Clinical efficacy of zinc supplementation in improving antioxidant defense system: A comprehensive systematic review and time-response meta-analysis of controlled clinical trials. Eur J Pharmacol. 2021;907:174243. https://doi.org/10.1016/j.ejphar.2021.174243.

30. Vela G., Stark P., Socha M., Sauer A., Hagmeyer S., Grabrucker A. Zinc in Gut- Brain Interaction in Autism and Neurological Disorders. Neural Plast. 2015;2015:972791. https://doi.org/10.1155/2015/972791.

31. Shishkova V.N., Nartsissov Y.R., Titova V.Y., Sheshegova E.V. Molecular mechanisms defining application of glycine and zinc combination in correction of stress and anxiety main manifestations. Farmatsiya i Farmakologiya. 2022;(5):404–415. (In Russ.) https://doi.org/10.19163/2307-9266-2022-10-5-404-415.

32. Mashkovtseva E.V., Nartsissov Y.R. Molecular mechanism of possible use of metabolites for prevention, therapy and rehabilitation of patients with COVID- 19. Molecular Medicine. 2021:(6):11–18. (In Russ.) Available at: https://molmedjournal.ru/ru/24999490-2021-06-02.

33. Samushia M.A., Kryzhanovsky S.M., Ragimova A.A., Berishvili T.Z., Chorbinskaya S.A., Ivannikova E.I. COVID- 19 effect on mental health and sleep disorders. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2021;121(4-2):49–54. (In Russ.) https://doi.org/10.17116/jnevro202112104249.

34. Podoprigora G.I., Nartsissov Y.R., Aleksandrov P.N. Effect of glycine on microcirculation in pial vessels of rat brain. Bulletin of Experimental Biology and Medicine. 2005;139(6):675–677. (In Russ.) https://doi.org/10.1007/s10517-005-0375-2.

35. Podoprigora G.I., Blagosklonov O., Angoué O., Boulahdour H., Nartsissov Y.R. Assessment of microcirculatory effects of glycine by intravital microscopy in rats. Annu Int Conf IEEE Eng Med Biol Soc. 2012;2012:2651–2654. https://doi.org/10.1109/EMBC.2012.6346509.

36. Nartsissov Y.R., Tyukina E.S., Boronovsky S.E., Sheshegova E.V. Computer modeling of spatial-time distribution of metabolite concentrations in phantoms of biological objects by example of rat brain pial. Biofizika. 2013;58(5):703–711. (In Russ.) https://doi.org/10.1134/S0006350913050102.

37. Nartsissov Y.R. The Effect of Flux Dysconnectivity Functions on Concentration Gradients Changes in a Multicomponent Model of Convectional Reaction Diffusion by the Example of a Neurovascular Unit. Scientific.Net. 2021;413:19–28. https://doi.org/10.4028/www.scientific.net/DDF.413.19.

38. Nartsissov Y.R. Application of a multicomponent model of convectional reaction-d iffusion to description of glucose gradients in a neurovascular unit. Front Physiol. 2022;13:843473. https://doi.org/10.3389/fphys.2022.843473.

39. Blagosklonov O., Podoprigora G.I., Davani S., Nartsissov Y.R., Comas L., Boulahdour H., Cardot J.C. FDG-PET scan shows increased cerebral blood flow in rat after sublingual glycine application. Nucl Instrum Methods Phys Res A. 2007;571(1-2):30–32. https://doi.org/10.1016/j.nima.2006.10.022.